sulphonylureas


Also found in: Dictionary.

sul·fo·nyl·u·re·as

(sŭl'fō-nil-yūr'ē-ăz)
Derivatives of isopropylthiodiazylsulfanilamide, chemically related to the sulfonamides, which possess hypoglycemic action. Belonging to this series are acetohexamide, azepinamide, chlorpropamide, fluphenmepramide, glymidine, hydroxyhexamide, heptolamide, indylamide, thiohexamide, tolazamide, and tolbutamide.
Synonym(s): sulphonylureas.

sulphonylureas

A class of drugs used in the treatment of maturity onset (Type II), non-insulin dependency DIABETES. They are taken by mouth. Also known as oral hypoglycaemic drugs. Examples are glibenclamide (Daonil, Euglucon), gliclazide (Diamicron), glimepiride (Amaryl), glipizide (Glibenese, Minodiab), gliquidone (Glurenorm) and repaglinide (Novonorm).

sul·fo·nyl·u·re·as

(sŭl'fō-nil-yūr'ē-ăz)
Derivatives of isopropylthiodiazylsulfanilamide, chemically related to sulfonamides, whichpossess hypoglycemic action (e.g., acetohexamide, tolbutamide).
Synonym(s): sulphonylureas.
References in periodicals archive ?
The UKPDS showed that 53% of T2DM patients using only sulphonylureas required insulin after 6 years and 80% after 9 years.
Metformin was the most commonly prescribed drug, followed by second generation sulphonylureas.
The research, carried out at the Biomedical Research Institute at the University of Dundee, looked at 1,073 people with Type 2 diabetes who had been treated with sulphonylureas for up to 18 months.
Chlorpropamide, used as the standard hypoglycemic agent in this study, is a member of the 'first-generation' sulphonylureas. As a class, sulphonylureas enhance and increase the release of endogenous insulin from pancreatic [beta]-cells.
Rajpathak, "Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis," Diabetic Medicine, vol.
A combination of metformin and sulphonylureas: This is recommended for the diabetic patients who are over-weight obese and having increased insulin resistance along with reduced production of insulin.
A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol.
Those taking sulphonylureas as their only therapy had up to 61% more chance of death and a 30% increased risk of heart failure compared with those taking metformin.
Experts insist that a drug commonly used to treat type 2 diabetes - sulphonylureas - can lead to hypoglycaemia.
(1) Oral antidiabetic agents, in particular the sulphonylureas (SUs), so far lack this degree of post-approval evaluation.
Evidence suggests that regular measurement of HbA1C in people with type 2 diabetes who are not on sulphonylureas or insulin is as effective in guiding treatment recommendations as regular SBGM.
Interestingly, we have recently demonstrated that the insulinotropic effect of stevioside unlike the classical sulphonylureas is not associated with closure of the ATP sensitive potassium channels in the beta cells (Jeppesen et al., 2000).